Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
about
Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in GermanyRegistered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulationsSelective Targeting of the L858R Mutation (EGFR) in Non-Small Cell Lung Cancer: A Mechanism for Advancing Targeted Chemotherapy.EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.Presence of cancer-associated mutations in exhaled breath condensates of healthy individuals by next generation sequencing.Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNAClinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor TherapyCoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network.Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4.Clinical potential of gene mutations in lung cancer.RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFRFrequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer.The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutationOncogene-Selective Sensitivity to Synchronous Cell Death following Modulation of the Amino Acid Nutrient Cystine.Noninvasive Bioluminescence Imaging of AKT Kinase Activity in Subcutaneous and Orthotopic NSCLC Xenografts: Correlation of AKT Activity with Tumor Growth Kinetics.Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective.JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines.A genetic interaction analysis identifies cancer drivers that modify EGFR dependency.Combine and conquer: challenges for targeted therapy combinations in early phase trials.A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: clinical implications of the LUX-Lung 7 studyBiomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patientsMarsdenia tenacissima extract overcomes Axl- and Met-mediated erlotinib and gefitinib cross-resistance in non-small cell lung cancer cells.High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.Are we ready to introduce T790M plasma analysis in the follow up of patients with NSCLC under treatment with EGFR-TKI?Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer.Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.Anti-proliferative and pro-apoptotic effects induced by simultaneous inactivation of HER1 and HER2 through endogenous polyclonal antibodies.Molecular Targets in Non-Small Cell Lung Cancer.APRIL promotes non-small cell lung cancer growth and metastasis by targeting ERK1/2 signaling.ER stress signaling promotes the survival of cancer 'persister cells' tolerant to EGFR tyrosine kinase inhibitors.The rocky road to personalized medicine in acute myeloid leukaemia.
P2860
Q28072203-F2AF02D7-EE0B-475D-89DF-EBF0A3341466Q28603408-D5BD6BB5-9574-4B6E-91C9-BA35AF19BB70Q30403022-B8EBA38A-4742-4A2D-9D1B-34DB12EB5BF8Q33276007-4ED2E025-E5C7-47DA-86ED-A13899D014CAQ33566859-CE83122B-FA07-465C-9C13-7C6ECFB97171Q33737740-9D653898-ADA8-41D2-9F81-92E8D185FBD2Q33779181-F99C5BB9-2806-4AAD-BD29-AE4ECF6CB26EQ33925570-85C54EC3-E479-49F3-AA07-51DC6F3A6EB4Q36138884-1E87AD1C-8794-4E37-9762-F83BBBD473B0Q36264188-E6153B17-F715-4AFB-9DF8-5D6046597A11Q36270828-0CAD3BF2-0E1D-40D2-AF50-3A3561F7F11DQ36310219-3B82F0FD-B404-4A2D-A731-E9534A19E556Q36316009-11665181-4253-464C-B9E9-5F296AE2306DQ36566472-20B9658A-0047-452C-AA52-B87125D2764DQ37085219-569819B1-F3C4-4B37-9235-5C4B5AA9DC44Q37086009-734512B1-54CF-47E9-83DD-3239202D3757Q37280403-262F0C5E-F2D3-4313-938C-65FA528F4FB2Q37285973-9EC25FEF-4077-45CD-8459-2A2773143064Q37536556-7C5B19E7-4427-4CAC-AB07-FE69EDC1ADF0Q37723730-3A9F6FB7-2AC8-4FCB-8AD0-677B6DC71997Q37736706-EF172730-A4DC-4C4E-BD64-DE76FF3E32B0Q38685481-E77C0CAB-55A4-413C-B3E2-472FB2A8D519Q38701688-BB4FBD29-5B13-4E49-954E-0D3AD40B55CAQ38717620-F3A9AC10-F180-4153-A4D1-58C8CC4016D9Q38734451-5E409206-0223-40C9-BF99-DD79FAB0BF71Q38806879-DF9EC0EC-DD0C-4798-B9D4-417945C23901Q38991958-4B44D560-2B92-479F-95FB-CAC945AC63D9Q40960371-45A2520E-4A1E-4CA0-8BD4-B740CEEBB94BQ41340872-EF9A472B-6CF5-4C5E-BF53-37F63C2E4AEEQ41344145-C4D90D3E-3159-4A57-A3CA-9AF915C4971DQ41523237-6F763B2D-DD14-4004-914D-C5500AA7A62FQ42330847-05341CDA-9025-4248-8A4D-2F19DC746F25Q42376338-9CD5EA10-6DDB-4B7D-B408-4FF893B1241AQ45122871-ECC36A77-B23A-4264-9722-A199066AA7FDQ45215365-5FE0DF24-F585-4739-8569-32E2084992B3Q47111722-1476C6DC-D88B-411A-89C9-BD23088AFECBQ47141828-E1DC2BE1-7DF7-4912-867D-36F6645CD40CQ47193701-8270BDCF-AD15-4086-8CF5-BC49BFA380C2Q47273602-2550EF81-74DF-462B-8F48-9A6644EED0BDQ47561008-7D3AF1DC-4483-408F-8BA3-2B6EFEB46C54
P2860
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Known and putative mechanisms ...... with EGFR mutations-a review.
@en
type
label
Known and putative mechanisms ...... with EGFR mutations-a review.
@en
prefLabel
Known and putative mechanisms ...... with EGFR mutations-a review.
@en
P2860
P1476
Known and putative mechanisms ...... with EGFR mutations-a review.
@en
P2093
Erin L Stewart
Samuel Zhixing Tan
P2860
P356
10.3978/J.ISSN.2218-6751.2014.11.06
P577
2015-02-01T00:00:00Z